Skip to content

Half effective dose of cyclobuprofenol during compound alfentanil to inhibit body movements during dilatation in patients undergoing hysteroscopic surgery

Half effective dose of cyclobuprofenol during compound alfentanil to inhibit body movements during dilatation in patients undergoing hysteroscopic surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081765
Enrollment
Unknown
Registered
2024-03-11
Start date
2024-03-11
Completion date
Unknown
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body movement during dilatation

Interventions

case senes:Alfentanil combined with cyclobenzaprine

Sponsors

Hangzhou Red Cross Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients who met the surgical criteria for proposed painless hysteroscopic surgery; 2. Age 25-55 years old, BMI 18.9-23.9kg/m2; 3. ASA Class I or II, NYHA Class I or II; 4. No obvious abnormality in preoperative tests and examinations; 5. Preoperative evaluation without difficult airway.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or breastfeeding; 2. Contraindication to general anesthesia or history of anesthetic accident; 3. Allergy to or contraindication to cypropofol, opioids; 4. Having serious heart, lung, liver, kidney, brain and other major diseases; 5. Abuse or long-term use of anesthesia, sedative, analgesic drugs; 6. Have mental illness or inability to communicate.

Design outcomes

Primary

MeasureTime frame
Body movement;Adverse events;ED50;ED95;

Secondary

MeasureTime frame
Vital signs (SBP, MAP, HR, SpO2, entropy index);

Countries

CHINA

Contacts

Public ContactDeying Kang

Hangzhou Red Cross Hospital

kdy_15855133919@qq.com+86 186 5812 3831

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026